Canaccord Genuity maintains Alnylam Pharmaceuticals at Buy, lowers price target to $323 from $429
Canaccord Genuity kept Alnylam Pharmaceuticals' rating at Buy but reduced its price target to $323 from $429, a 24.7% decrease. This implies a 119.5% upside from the Oct 30 close of $147.17. Recent analyst price targets for Alnylam range from $199 to $354.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns about growth prospects, likely prompting short‑term sell‑offs.
Market read
Analyst target cuts can trigger immediate price adjustments, especially in high‑growth biotech stocks.
What to watch
Potential upcoming data from Alnylam's pipeline could offset the target reduction if positive.
Background
Alnylam Pharmaceuticals is a leading RNA‑interference drug developer; analyst price‑target changes are common catalysts for short‑term moves.
Ticker impact
Canaccord Genuity lowered its price target on Alnylam Pharmaceuticals to $323 from $429, indicating a bearish analyst view.
likely pressure as investors price in the lower target
A 24.7% cut in price target signals reduced expectations for future performance, which typically leads to selling pressure.
Market effects
May weigh on other RNA‑therapeutics peers as analysts reassess valuation multiples.
Limited to US biotech sector.
Minimal global impact.
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity at current levels.
Key entities
- Analyst FirmCanaccord Genuity
Equity research firm that issued the revised price target.
- CompanyAlnylam Pharmaceuticals
Biotech firm developing RNA‑based therapeutics.
